PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Voss, M. H.; Tykodi, S. S.; Grimm, M. O.; Hammers, H. J.; Rini, B. I.; Tannir, N. M.; Qureshi, A. H.; Tsipouri, V.; Hodari, M.; Ravimohan, S.; Reimers, M. A. |
| Abstract Title: | PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900408 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.TPS403 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS403 -- Meeting was conducted online as well as in person -- Source: Wos |
